An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines

Prostate

Volumn 66, Issue 12, 2006, Pages 1245-1256

  Diallo, Jean Simon ^a   Péant, Benjamin ^a   Lessard, Laurent ^a   Delvoye, Nathalie ^a   Le Page, Cécile ^a   Mes Masson, Anne Marie ^a,b   Saad, Fred ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

Author keywords

Androgen receptor; Androgen independent prostate cancer; E2F, NF B; Inositol hexakisphosphate

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; DNA FRAGMENT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 2; PHYTIC ACID; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; ANDROGEN; CASP3 PROTEIN, HUMAN; CASPASE; DNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL METABOLISM; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; APOPTOSIS; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; APOPTOSIS; CASPASE 3; CASPASES; CELL LINE, TUMOR; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NF-KAPPA B; PHYTIC ACID; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748372700     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20455     Document Type: Article

References (54)

1. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72(12 Suppl):3888-3895.
2. Feldman B, Seidman DS, Levron J, Bider D, Shulman A, Shine S, Dor J. In vitro fertilization following natural cycles in poor responders. Gynecol Endocrinol 2001;15(5):328-334.
3. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, et al. Regulation of androgen action. Vitam Horm 1999;55:309-352.
4. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9(3):601-610.
5. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, et al. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 1998;248(2):361-367.
6. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res 2003;63(16):4903-4913.
7. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, Ikeda K, et al. Cyclin E as a coactivator of the androgen receptor. J Cell Biol 2000;150(4):873-880.
8. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA. Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 1996;271(39):24151-24156.
9. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001;98(13):7200-7205.
10. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001;47(1):66-75.
11. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
12. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52(24):6940-6944.
13. Ratan HL, Gescher A, Steward WP, Mellon JK. ErbB receptors: Possible therapeutic targets in prostate cancer? BJU Int 2003;92(9):890-895.
14. Gavrielides MV, Frijhoff AF, Conti CJ, Kazanietz MG. Protein kinase C and prostate carcinogenesis: Targeting the cell cycle and apoptotic mechanisms. Curr Drug Targets 2004;5(5):431-443.
15. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS, et al. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003;9(1):391-401.
16. Edwards J, Krishna NS, Mukherjee R, Bartlett JM. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 2004;204(2):153-158.
17. Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: An early perspective. Endocr Relat Cancer 2003;10(4):537-560.
18. Libertini SJ, Tepper CG, Guadalupe M, Lu Y, Asmuth DM, Mudryj M. E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis. Prostate 2006;66(1):70-81.
19. Le Page C, Koumakpayi IH, Lessard L, Saad F, Mes-Masson AM. Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate 2005;65(4):306-315.
20. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 2005;65(2):130-140.
21. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003;91(4):417-420.
22. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52(3):183-200.
23. McCarty MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy. Integr Cancer Ther 2004;3(4):349-380.
24. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3(10):768-780.
25. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: From laboratory to clinic. J Nutr 2003;133(11 Suppl 1):3778S-3784S.
26. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: A systematic review. Complement Ther Med 2002;10(4):229-234.
27. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexaphosphate inhibits constitutive activation of NF- kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res 2003;23(5A):3855-3861.
28. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000;21(12):2225-2235.
29. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: Modulation of CDK1-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003;24(3):555-563.
30. Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 1991;51(23 Pt 1):6280-6285.
31. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29(9):e45.
32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-386.
33. Bilbault P, Lavaux T, Lahlou A, Uring-Lambert B, Gaub MP, Ratomponirina C, et al. Transient Bcl-2 gene down-expression in circulating mononuclear cells of severe sepsis patients who died despite appropriate intensive care. Intensive Care Med 2004;30(3):408-415.
34. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid II: Effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 2005;86(2):436-443.
35. Tanaka R, Ariyama H, Qin B, Shibata Y, Takii Y, Kusaba H, et al. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol Rep 2005;14(3):683-688.
36. Shah RB, Palamakula A, Khan MA. Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin. J Pharm Sci 2004;93(4):1070-1082.
37. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction. Biotechnol Annu Rev 2005;11:127-152.
38. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines-part 1. J Urol 2005;173(2):342-359.
39. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines-part 2. J Urol 2005;173(2):360-372.
40. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997;126(1):59-73.
41. Ferry S, Matsuda M, Yoshida H, Hirata M. Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkappaB-mediated cell survival pathway. Carcinogenesis 2002;23(12):2031-2041.
42. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371(6495):346-347.
43. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376(6535):37-43.
44. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression of inhibitor I kappa B alpha: Evidence for an inducible autoregulatory pathway. Science 1993;259(5103):1912-1915.
45. Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS Jr. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol 2001;21(24):8428-8436.
46. Cha Y, Deisseroth AB. Human interferon regulatory factor 2 gene. Intron-exon organization and functional analysis of 5′-flanking region. J Biol Chem 1994;269(7):5279-5287.
47. Dang ZC, Lowik CW. Removal of serum factors by charcoal treatment promotes adipogenesis via a MAPK-dependent pathway. Mol Cell Biochem 2005;268(1-2):159-167.
48. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005;24(45):6773-6784.
49. Davis R, Jia D, Cinar B, Sikka SC, Moparty K, Zhau HE, et al. Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation. Biochem Biophys Res Commun 2003;309(4):937-945.
50. Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 1995;16(8):1975-1979.
51. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, et al. NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 2003;17(7):1349-1356.
52. Dimova DK, Dyson NJ. The E2F transcriptional network: Old acquaintances with new faces. Oncogene 2005;24(17):2810-2826.
53. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1998;1(4):543-551.
54. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2(4):301-310.